Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;73(6):968-72.
doi: 10.1111/j.1365-2125.2012.04247.x.

Pharmacoeconomics

Dyfrig A Hughes  1
Affiliations

Pharmacoeconomics

Dyfrig A Hughes. Br J Clin Pharmacol. 2012 Jun.

Abstract

Pharmacoeconomics is an essential component of health technology assessment and the appraisal of medicines for use by UK National Health Service (NHS) patients. As a comparatively young discipline, its methods continue to evolve. Priority research areas for development include methods for synthesizing indirect comparisons when head-to-head trials have not been performed, synthesizing qualitative evidence (for example, stakeholder views), addressing the limitations of the EQ-5D tool for assessing quality of life, including benefits not captured in quality-adjusted life years (QALYs), ways of assessing valuation methods (for determining utility scores), extrapolation of costs and benefits beyond those observed in trials, early estimation of cost-effectiveness (including mechanism-based economic evaluation), methods for incorporating the impact of non-adherence and the role of behavioural economics in influencing patients and prescribers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A schematic representation of the components of a mechanism-based economic evaluation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hughes DA. From NCE to NICE: the role of pharmacoeconomics. Br J Clin Pharmacol. 2010;70:317–9. - PMC - PubMed
    1. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329:224–7. - PMC - PubMed
    1. Longworth L, Sculpher MJ, Bojke L, Tosh JC. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence. Int J Technol Assess Health Care. 2011;27:180–7. - PubMed
    1. Dolan P, Hallsworth M, Halpern D, King D, Vlaev I. Mindspace: influencing behaviour through public policy. 2010. Institute for Government and the Cabinet Office (Discussion document) Available at http://www.instituteforgovernment.org.uk/sites/default/files/publication... (last accessed 16 March 2012)
    1. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15:677–87. - PubMed

Substances